NUVB — Nuvation Bio Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1811063 ·
Last close
$6.76
Market Cap
$2.37B
52W High
$7.58
52W Low
$4.45
ADV30
6,114,663
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 31,687,000 | 22,216,000 | -51,036,000 | -62,840,000 | 744,503,000 | 258,604,000 | 490,639,000 |
| Mar 2026 | 83,228,000 | 77,237,000 | 3,881,000 | 5,397,000 | 610,241,000 | 125,391,000 | 290,677,000 |
| Dec 2025 | 41,865,000 | 40,586,000 | -34,037,000 | -36,592,000 | 594,822,000 | 164,086,000 | 289,106,000 |
| Sep 2025 | 13,120,000 | 9,771,000 | -56,434,000 | -55,792,000 | 601,561,000 | 98,897,000 | 275,679,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-120,522,000
Investing CF
$-47,183,000
Financing CF
$179,137,000
CapEx
$-8,403,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.44
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,172,813,000
Inventory
$19,901,000
Receivables
$31,714,000
ST Investments
$402,352,000
EBIT TTM
$-123,153,000
Pretax Income TTM
$-149,827,000
Interest Exp TTM
$26,674,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$169,900,000
EBITDA
$-135,480,992
Free Cash Flow
$-112,112,496
Enterprise Value
$2,188,591,104
Total Cash
$660,956,032
Total Debt
$416,263,008
Shares Out
350,123,233
Trailing EPS
$-0.44
Book Value
$0.73
ROE
-47.8%
ROA
-12.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 62,902,000 | -213,064,000 | -204,627,000 | 594,822,000 | 289,106,000 | — | -173,427,000 |
| Dec 2024 | 7,873,000 | -167,557,000 | -567,939,000 | 540,626,000 | 76,838,000 | — | -130,413,000 |
| Dec 2023 | 0 | -99,822,000 | -75,802,000 | 621,484,000 | 16,362,000 | — | -67,999,000 |
| Dec 2022 | 0 | -119,734,000 | -104,199,000 | 672,141,000 | 17,065,000 | — | -96,108,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.01
Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $6.76 · call volume: 549 · put volume: 7
Expected Move to 2026-09-18:
±$1.15
(17.01%) —
implied range
$5.61 –
$7.91
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RAPP | Rapport Therapeutics, Inc. | $2.37B | $49.33 | — |
| OCUL | OCULAR THERAPEUTIX, INC | $2.37B | $10.78 | — |
| VERA | Vera Therapeutics, Inc. | $2.43B | $33.72 | — |
| GIFOF | Grifols SA | $2.29B | $8.85 | — |
| GENB | Generate Biomedicines, Inc. | $2.27B | $17.72 | — |
News headlines (Yahoo Finance, 1h cache)
JPMorgan sees 100% upside in overlooked cancer drug stock
2026-08-20 22:07 · Yahoo
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
2026-08-20 12:00 · Yahoo
Wall Street Analysts Predict a 105.71% Upside in Nuvation Bio (NUVB): Here's What You Should Know
2026-08-18 13:55 · Yahoo
Nuvation Bio Q2 Earnings Call Highlights
2026-08-08 21:03 · Yahoo
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates
2026-08-06 13:50 · Yahoo
Do IBTROZI’s TRUST Data Shape Nuvation Bio’s (NUVB) Edge in Targeted Lung Cancer Therapy?
2026-08-04 16:16 · Yahoo
Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
2026-08-04 12:00 · Yahoo
Nuvation Bio Inc. (NUVB) Expected to Beat Earnings Estimates: Should You Buy?
2026-07-30 14:00 · Yahoo
Nuvation Bio's Safusidenib Clinical Program, Ibtrozi Opportunity Create Favorable Setup, RBC Says
2026-07-22 16:52 · Yahoo
Nuvation Bio (NUVB) Soars 7.9%: Is Further Upside Left in the Stock?
2026-07-21 14:08 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.